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141 A retrospective review of non-tuberculous mycobacteria in
paediatric cystic ﬁbrosis patients at a regional centre
S. Ager1, C. O’Brien2, D.A. Spencer2, A. Robb1. 1RVI, Microbiology, Newcastle
upon Tyne, United Kingdom; 2RVI, Respiratory Medicine, Newcastle upon Tyne,
United Kingdom
Non-tuberculous mycobacteria (NTM) are increasingly isolated from CF patients.
We carried out a retrospective review of respiratory specimens from paediatric
patients at a regional CF centre to assess the possible signiﬁcance of NTM.
Samples from 158 patients were reviewed. 7 patients (4%) were identiﬁed as having
NTM isolated from at least one clinical specimen (4 male, 3 female, age range
when NTM ﬁrst isolated 7−12 yrs). The sample type of ﬁrst isolation was a
bronchoalveolar lavage (BAL) in 2 cases, sputum in 3 cases and cough swab in
2 cases. The NTM isolated were M avium complex (MAC) (n = 3), M. chelonae
(n = 3) and M abscessus (n = 1). Initial NTM positive samples were isolated from
1 patient in 2007, 3 patients in 2008, 2 in 2009 and 1 in 2010.
None of the initial positive samples (BALs or sputums) were smear positive,
although one patient with an initial smear negative, culture positive sputum was
smear positive on a follow-up BAL.
All isolates were initially sensitive in vitro to azithromycin and clarithromycin.
Only one patient was treated for NTM infection. MAC was isolated from a BAL
following deterioration in respiratory symptoms; Burkholderia vietnamiensis was
also isolated and he received dual treatment with ciproﬂoxacin and azithromycin
and was showing an improvement in respiratory function at 3 months. All patients
had other potential pathogens isolated with NTM, including Aspergillus sp. (n = 4).
Three patients received steroids for treatment of ABPA prior to isolation of NTM.
Identifying whether NTM represents colonisation or infection is difﬁcult and may
be complicated by other organisms; trial of therapy with assessment of response
may be indicated.
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Aim: To determine whether we could detect the presence and carriage rate of three
organisms known to cause atypical infection in immunocompromised hosts, in the
sputa of 150 CF patients using sensitive nested PCR.
Methods: 190 sputum samples were collected from 150 patients attending Heart-
lands Hospital between November 2009–November 2010. Duplicate samples col-
lected were analysed and included in the ﬁnal analysis. DNA was extracted from
these sputa and nested double round PCR for P. jirovecii, M. pneumoniae and
C. pneumoniae was performed on all samples, with the results investigated by gel
electrophoresis.
Results: 6 patients were found to be PCR positive for P. jirovecii, consistent with
a 4.3% carriage rate in this cohort. Repeat samples taken from initially negative
patients remained negative on repeat analysis. Induced sputum was obtained from
5 of these patients and re-analysed after 6−8 months. All had become P. jirovecii
negative on repeat PCR testing. Furthermore, none of the 190 samples was found
to be positive for M. pneumoniae or C. pneumoniae suggesting that CF patients are
not carriers of these organisms.
Discussion: We detected a carriage rate of 4.3% for P. jirovecii, this is lower than
previously reported (7.4%) [1]. No patients had clinical features of infection with
P. jirovecii suggesting that CF patients may act as a transient reservoir for infection.
We suggest that P. jirovecii should be considered as a potential pathogen and may
warrant treatment if there is poor response to standard therapy
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Introduction and Aims: CF and non-CF bronchiectasis are characterised by
chronic lung infection and subsequent decline in function. Areas of low oxygen ten-
sion have been identiﬁed within the lungs of these patients and anaerobes have been
isolated with Prevotella spp. predominating. Prevotella spp. are well characterised
oral pathogens, and are also suspected of involvement in pulmonary infection. This
study aimed to examine the molecular epidemiology of Prevotella spp.
Methods: Isolates were cultured under strict anaerobic conditions from CF sputum
(n = 5), oral plaque (n = 5), non-CF sputum (n = 4) and a type strain was acquired
from the American Type Culture Collection [ATCC (n = 1)]. All isolates were
identiﬁed by 16s rDNA sequencing and then characterised by PFGE, using XbaI.
Results: Comparison of isolates by PFGE (n = 15) grouped isolates into two
pulsotypes [Clusters A (n = 5) and B (n = 8)], with 56% similarity between each
cluster. A further 2 isolates had only one band and were not included in the com-
parison. Each cluster included Prevotella from several species (P. melaninogenica,
P. nigrescens and P. salivae). There appears to be no distinct relationship between
disease state and pulsotype. A high degree of inter-species homology, as determined
by PFGE (e.g. 91% between P. denticola and P. nigrescens) was apparent. Analysis
of isolates (n = 3) in duplicate showed high levels of reproducibility (95−100%).
Conclusion: Initial PFGE studies have identiﬁed two main pulsotypes among
Prevotella spp. examined. Whilst PFGE may provide a useful tool for understanding
the molecular epidemiology of clinical Prevotella spp., it requires validation using
further isolates.
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Objective: To assess the value of bronchoscopy and bronchoalveolar lavage (BAL) in patients with
CF and radiological features of ‘atypical infection’.
Method: Clinical, microbiological and radiological data was retrospectively collected for all patients
who had undergone bronchoscopy between 2005 and 2010. Data for individuals where the primary
indication for BAL was features of ‘atypical infection’ on HRCT was subsequently analysed.
Results: A total of 29 bronchoscopies were undertaken. Ten procedures in 8 patients were as a direct
result of HRCT appearance. In ﬁve, BAL identiﬁed a signiﬁcant pathogen which had not been isolated
from sputum.
Table 1
23/F CT: Nodules Sputum: M. chelonae (MC),
S. maltophilia (SM)
BAL: MC, SM,
A. fumigatus (AF)
AF − Started
antifungal Rx
30/M CT: Nodules, tree in bud Sputum: Mucoid
P. aeruginosa (PA)
BAL: Mucoid PA No Rx change
66/M CT: Mucus plugging and
ground-glass change, the soft
tissue within the bronchus was
of high attenuation.
Sputum: PA BAL: PA, AF AF-already on
antifungal Rx
28/F CT: consolidation, dilated
mucous ﬁlled bronchi
Sputum: Penicillium sp BAL: No pathogen
isolated
No Rx change
25/M CT: soft tissue attenuation of
endobronchial material
Sputum: PA, mucoid PA BAL: PA, mucoid PA No Rx change
18/F CT: Nodules Sputum: SM, AF BAL: AF No Rx change
28/F CT: Nodules Sputum: MRSA BAL: MRSA, PA,
adenovirus, EBV
Adenovirus, EBV,
PA − already on Rx
No Rx change
24/F CT: Nodules Sputum: PA, mucoid PA BAL: PA, mucoid PA No Rx change
24/F CT: Nodules Sputum: PA, mucoid PA,
adenovirus, rhinovirus
BAL: PA, mucoid PA,
adenovirus, rhinovirus,
M. intracellulare (MI)
MI − No growth on
subsequent BAL No
Rx change
24/F CT: Nodules Sputum: PA, mucoid PA BAL: PA, mucoid PA,
adenovirus
Adenovirus No Rx
change
In six procedures, no ‘atypical organism’ was identiﬁed. Only one patient had their treatment
changed following BAL although results were used to conﬁrm diagnosis and continued treatment.
The remaining cases had commenced appropriate therapy pre-bronchoscopy guided by sputum
microbiology, past medical history and clinical presentation.
Conclusion: Nodular changes on HRCT are not always due to atypical infection. While the majority of
patients had been started on appropriate treatment, BAL was useful in guiding long term management.
